vs
Apellis Pharmaceuticals, Inc.（APLS）与Employers Holdings, Inc.（EIG）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Employers Holdings, Inc.的1.2倍（$199.9M vs $170.5M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -21.3%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -11.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Employers Holdings, Inc.是总部位于美国的保险控股企业，主营劳工赔偿保险产品，主要面向美国境内中小微企业客户，同时提供定制化风险管理解决方案，服务覆盖多类中低风险行业，助力客户管控工作场所安全风险、满足员工保障相关合规要求。
APLS vs EIG — 直观对比
营收规模更大
APLS
是对方的1.2倍
$170.5M
营收增速更快
APLS
高出15.3%
-21.3%
两年增速更快
APLS
近两年复合增速
-11.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $170.5M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -21.3% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEIG
| Q1 26 | — | $170.5M | ||
| Q4 25 | $199.9M | $188.5M | ||
| Q3 25 | $458.6M | $239.3M | ||
| Q2 25 | $178.5M | $246.3M | ||
| Q1 25 | $166.8M | $202.6M | ||
| Q4 24 | $212.5M | $216.6M | ||
| Q3 24 | $196.8M | $224.0M | ||
| Q2 24 | $199.7M | $217.0M |
净利润APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-8.3M | ||
| Q2 25 | $-42.2M | $29.7M | ||
| Q1 25 | $-92.2M | $12.8M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $30.3M | ||
| Q2 24 | $-37.7M | $31.7M |
营业利润率APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -4.7% | ||
| Q2 25 | -18.6% | 15.0% | ||
| Q1 25 | -50.0% | 7.8% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 16.4% | ||
| Q2 24 | -14.7% | 18.4% |
净利率APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -3.5% | ||
| Q2 25 | -23.6% | 12.1% | ||
| Q1 25 | -55.3% | 6.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 13.5% | ||
| Q2 24 | -18.9% | 14.6% |
每股收益（稀释后）APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $-0.93 | ||
| Q3 25 | $1.67 | $-0.36 | ||
| Q2 25 | $-0.33 | $1.23 | ||
| Q1 25 | $-0.74 | $0.52 | ||
| Q4 24 | $-0.30 | $1.14 | ||
| Q3 24 | $-0.46 | $1.21 | ||
| Q2 24 | $-0.30 | $1.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $169.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $955.7M |
| 总资产 | $1.1B | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEIG
| Q1 26 | — | $169.9M | ||
| Q4 25 | $466.2M | $169.9M | ||
| Q3 25 | $479.2M | $172.4M | ||
| Q2 25 | $370.0M | $78.1M | ||
| Q1 25 | $358.4M | $100.4M | ||
| Q4 24 | $411.3M | $68.4M | ||
| Q3 24 | $396.9M | $173.9M | ||
| Q2 24 | $360.1M | $126.4M |
总债务APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | — | $19.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益APLSEIG
| Q1 26 | — | $955.7M | ||
| Q4 25 | $370.1M | $955.7M | ||
| Q3 25 | $401.2M | $1.0B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.0B |
总资产APLSEIG
| Q1 26 | — | $3.4B | ||
| Q4 25 | $1.1B | $3.4B | ||
| Q3 25 | $1.1B | $3.5B | ||
| Q2 25 | $821.4M | $3.5B | ||
| Q1 25 | $807.3M | $3.6B | ||
| Q4 24 | $885.1M | $3.5B | ||
| Q3 24 | $901.9M | $3.6B | ||
| Q2 24 | $904.5M | $3.5B |
负债/权益比APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $44.7M | ||
| Q3 25 | $108.5M | $29.4M | ||
| Q2 25 | $4.4M | $0 | ||
| Q1 25 | $-53.4M | $14.6M | ||
| Q4 24 | $19.4M | $76.4M | ||
| Q3 24 | $34.1M | $51.0M | ||
| Q2 24 | $-8.3M | $11.7M |
自由现金流APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $44.6M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $76.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 23.7% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 35.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSEIG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 1.14× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.68× | ||
| Q2 24 | — | 0.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EIG
暂无分部数据
